[Interferon alpha, gamma, omega before and during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin].
OBJECTIVE
assessment of interferon alpha, gamma, omega concentrations in patients with chronic hepatitis C before and during antiviral treatment and comparison of these parameters between chronically infected HCV and healthy individuals (control group).


METHODS
IFN alpha, gamma, omega concentrations were measured before and in 2, 12, 48 week during antiviral therapy in patients with chronic HCV infection treated with PegIFN plus ribavirin and in 30 cases of healthy individuals of control group.


RESULTS
Statistically significant differences in IFN alpha concentrations at different times of investigation in patients with chronic hepatitis C and in IFN alpha and omega concentrations in comparison to results obtained in control group and in patients before treatment were found. Concentrations of IFN gamma in 48 week and omega in "0" and 2 week of the treatment were higher in patients with GI,G2 than with G3. There were no statistically significant differences in IFN alpha, gamma, omega concentrations between patients with good or bad response to antiviral treatment at EVR, ETR, SVR and between patients with shorter or longer than 10 years of HCV infection.


CONCLUSIONS
1. IFN alpha was no detected in healthy individuals but was detected in 34% of patients with chronic hepatitis C. 2. IFN omega was present in each case from control group but only in less than 50% of chronically infected with HCV. 3. There was no correlation in IFN alpha, gamma and omega concentrations with efficacy of antiviral treatment.
Katedra i Klinika Chorób Zakaźnych Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu.
Beata
B
Bolewska
Arkadiusz
A
Czajka
Jerzy
J
Moczko
Jacek
J
Juszczyk
D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage; D016022:Case-Control Studies; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D007370:Interferon Type I / Q000097:blood* / Q000187:drug effects; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000097:blood* / Q000187:drug effects; D016899:Interferon-beta / Q000097:blood* / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage*; D016896:Treatment Outcome
D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; C063743:interferon omega 1; D011092:Polyethylene Glycols; D012254:Ribavirin; D016899:Interferon-beta; C100416:peginterferon alfa-2a